Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study

被引：0
|
作者：
Yang, Yunpeng
Zhao, Yuanyuan
Fang, Wenfeng
Huang, Yan
Zhang, Yaxiong
Ba, Yi
Wang, Zhen
Deng, Chao
Hu, Desheng
Wang, Wei
Li, Guiling
Luo, Suxia
Fu, Zhichao
Zhu, Haisheng
Wang, Huili
Zhao, Shiwei
Li, Tao
Cai, Charles
Zhang, Li
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT227
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of IBI110 (anti-LAG-3 antibody) plus sintilimab (anti-PD-1 antibody) in patients with advanced alveolar soft part sarcoma: Results from a phase II study
    Liu, Jiayong
    Tan, Zhichao
    Fan, Zhengfu
    Bai, Chujie
    Xue, Ruifeng
    Li, Shu
    Gao, Tian
    Zhang, Lu
    Wang, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma
    Kindler, Hedy Lee
    Karrison, Theodore
    Khattri, Arun
    Zuo, Zhixiang
    Sulai, Nanna
    Rose, Buerkley
    Ahmad, Mehwish I.
    Armato, Samuel
    Salgia, Ravi
    Seiwert, Tanguy
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S630 - S630
  • [33] An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
    Gordon, Michael S.
    Robert, Francisco
    Matei, Daniela
    Mendelson, David S.
    Goldman, Jonathan W.
    Chiorean, E. Gabriela
    Strother, Robert M.
    Seon, Ben K.
    Figg, William D.
    Peer, Cody J.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Rosen, Lee S.
    CLINICAL CANCER RESEARCH, 2014, 20 (23) : 5918 - 5926
  • [34] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
    Curigliano, Giuseppe
    Gelderblom, Hans
    Mach, Nicolas
    Doi, Toshihiko
    Tai, David
    Forde, Patrick M.
    Sarantopoulos, John
    Bedard, Philippe L.
    Lin, Chia-Chi
    Hodi, F. Stephen
    Wilgenhof, Sofie
    Santoro, Armando
    Sabatos-Peyton, Catherine A.
    Longmire, Tyler A.
    Xyrafas, Alexandros
    Sun, Haiying
    Gutzwiller, Sabine
    Manenti, Luigi
    Naing, Aung
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629
  • [35] Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
    Xu, Jianming
    Zhang, Yun
    Jia, Ru
    Yue, Chunyan
    Chang, Lianpeng
    Liu, Rongrui
    Zhang, Gairong
    Zhao, Chuanhua
    Zhang, Yaoyue
    Chen, Chunxia
    Wang, Yan
    Yi, Xin
    Hu, Zhiyuan
    Zou, Jianjun
    Wang, Quanren
    CLINICAL CANCER RESEARCH, 2019, 25 (02) : 515 - 523
  • [36] BGB-A317-LBL-007-202: A phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC)
    Park, Sook Ryun
    Chen, Ming-Huang
    Dechaphunkul, Arunee
    Ding, Ningning
    Lin, Xiao
    Zhang, Jinghui
    Li, Vivian
    Li, Qiao
    Ba, Yi
    CANCER RESEARCH, 2024, 84 (07)
  • [37] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Yamamoto, Noboru
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Shibata, Takashi
    Tamura, Yosuke
    Seki, Yoshitaka
    Honda, Kazunori
    Tanabe, Yuko
    Wakui, Hiroshi
    Tamura, Tomohide
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 207 - 216
  • [38] Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Takashi Shibata
    Yosuke Tamura
    Yoshitaka Seki
    Kazunori Honda
    Yuko Tanabe
    Hiroshi Wakui
    Tomohide Tamura
    Investigational New Drugs, 2017, 35 : 207 - 216
  • [39] Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: Results of an open-label phase II clinical study Polaris-03.
    Sheng, Xinan
    Chen, Haige
    Hu, Bin
    Yao, Xudong
    Liu, Ziling
    Yao, Xin
    Guo, Hongqian
    Hu, Yi
    Ji, Zhigang
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    Wu, Jin
    Zhou, Fangjian
    He, Zhisong
    Fan, Jinhai
    Huang, Yiran
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naive to anti-PD-1 therapy
    Long, G. V.
    Milhem, M.
    Amin, A.
    Hoimes, C. J.
    Medina, T.
    Conry, R. M.
    Lao, C.
    Daniels, G.
    Reddy, S.
    Mehmi, I.
    Andtbacka, R. H. I.
    Barve, M.
    Shaheen, M.
    Tueting, T.
    Chisamore, M.
    Xing, B.
    Candia, A.
    Gamelin, E.
    Janssen, R.
    Ribas, A.
    ANNALS OF ONCOLOGY, 2018, 29
12345